LogicBio Therapeutics, Inc. (LOGC)
Bronstein, Gewirtz & Grossman, LLC Announces Investigation of LogicBio Therapeutics, Inc. (LOGC)
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of LogicBio Therapeutics, Inc. (“LogicBio” or the Company”) (NASDAQ: LOGC). The investigation concerns whether LogicBio and certain of its officers and/or directors have violated federal securities laws.
On February 10, 2020, post-market, LogicBio issued a press release announcing “that the U.S. Food and Drug Administration (FDA) has placed a clinical hold on [LogicBio’s] Investigational New Drug (IND) submission for LB-001 for the treatment of methylmalonic acidemia (MMA) pending the resolution of certain clinical and nonclinical questions.” On this news, LogicBio’s stock price fell sharply during intraday trading on February 11, 2020.
If you are aware of any facts relating to this investigation, or purchased LogicBio shares, you can learn more about the investigation by contacting Peretz Bronstein or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.